
| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-02 | 2026-06-02 | Kent Mark D. | President - MSO | Purchase | 14.8K | $13.31 | $198K | 14.8K | View ↗ | |
| 2026-05-15 | 2026-05-19 | Maroney Dawn Christine | President | Sale | 30.0K | $16.09 | $483K | 998.8K | View ↗ | |
| 2026-05-11 | 2026-05-13 | KAO JOHN E | Director & Chief Executive Officer | Sale | 298.0K | $16.89 | $5.03M | 1.51M | View ↗ | |
| 2026-04-15 | 2026-04-15 | Maroney Dawn Christine | President | Sale | 30.0K | $20.87 | $626K | 1.03M | View ↗ | |
| 2026-04-13 | 2026-04-13 | KAO JOHN E | Director & Chief Executive Officer | Sale | 82.3K | $20.80 | $1.71M | 1.81M | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Earned premiums | $3.91B+46.4% | $2.67B+48.4% | $1.80B+25.8% | $1.43B+22.7% | $1.17B |
| Other | $37.0M+17.0% | $31.6M+39.4% | $22.7M+770.0% | $2.6M+279.2% | $688K |
| Total revenues | $3.95B+46.1% | $2.70B+48.3% | $1.82B+27.2% | $1.43B+22.8% | $1.17B |
| Medical expenses | $3.46B+43.8% | $2.41B+48.3% | $1.62B+29.8% | $1.25B+20.3% | $1.04B |
| Selling, general, and administrative expenses | $443.4M+19.4% | $371.4M+20.8% | $307.4M+4.0% | $295.6M+1.6% | $291.0M |
| Depreciation and amortization | $30.4M+13.1% | $26.9M+25.5% | $21.4M+24.0% | $17.3M+9.2% | $15.8M |
| Total expenses | $3.93B+40.2% | $2.81B+43.7% | $1.95B+24.9% | $1.56B+16.1% | $1.35B |
| Income (loss) from operations | $14.8M+114.5% | -$101.6M+20.5% | -$127.8M+0.6% | -$128.6M+27.8% | -$178.1M |
| Interest expense | $15.8M-32.9% | $23.5M+10.9% | $21.2M+16.1% | $18.3M+4.9% | $17.4M |
| Other income, net | -$89K-23.6% | -$72K+91.6% | -$853K-584.7% | $176K-99.0% | $17.2M |
| Loss on extinguishment of debt | $0-100.0% | $3.0M | $0-100.0% | $2.2M | $0 |
| Total other expenses | $15.7M-40.7% | $26.5M+30.0% | $20.4M-1.4% | $20.7M+20.0% | $17.2M |
| Loss before income taxes | -$958K+99.3% | -$128.1M+13.6% | -$148.2M+0.7% | -$149.3M+23.5% | -$195.3M |
| Total | $20K-4.8% | $21K+195.5% | -$22K-106.5% | $339K | $0 |
| Net loss | -$978K+99.2% | -$128.1M+13.6% | -$148.2M+1.0% | -$149.6M+23.4% | -$195.3M |
| Less: Net loss attributable to noncontrolling interest | -$254K-605.6% | -$36K+76.9% | -$156K-269.6% | $92K | $0 |
| Net loss attributable to Alignment Healthcare, Inc. | -$724K+99.4% | -$128.0M+13.5% | -$148.0M+1.0% | -$149.5M+23.4% | -$195.3M |
| Total weighted-average common shares outstanding - basic (in shares) | $198.01B+3.8% | $190.79B+2.5% | $186.21B+2.8% | $181.21B | — |
| Total weighted-average common shares outstanding - diluted (in shares) | $198.01B+3.8% | $190.79B+2.5% | $186.21B+2.8% | $181.21B | — |
| Net loss per share attributable to Alignment Healthcare, Inc. - basic (in dollars per share) | $0+100.0% | -$670+15.2% | -$790+4.8% | -$830+27.2% | -$1K |
| Net loss per share attributable to Alignment Healthcare, Inc. - diluted (in dollars per share) | $0+100.0% | -$670+15.2% | -$790+4.8% | -$830+27.2% | -$1K |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Alignment Healthcare Named to the Fortune 1000 2026 List for Second Consecutive Year
Alignment Healthcare (ALHC) Announces Executive Leadership Updates as John Kao Assumes Role of Chairman
Down 25.5% in 4 Weeks, Here's Why Alignment Healthcare (ALHC) Looks Ripe for a Turnaround
A Look At Alignment Healthcare (ALHC) Valuation After Analyst Downgrades And A Sharp 30-Day Share Price Slide